Nigel Hawkes, Health Editor
Download 'Too Hot', an exclusive Specials track from iTunes
Another new cancer drug has been rejected by the Government’s value-for-money watchdog.
Roche, the healthcare company that makes Tarceva, used to treat lung cancer, said that it would appeal against the decision by the National Institute for Health and Clinical Excellence (NICE), which it said was perverse and disappointing.
It claimed that the evidence Roche presented had been assessed “neither fairly nor appropriately” by NICE. Tarceva has been approved for use in Scotland since June 2006.
The NICE guidance said it did not believe that Tarceva (erlotinib) was the best use of resources in the care of sufferers of non-small cell lung cancer. It said that the drug would be reviewed again next year.
Andrew Dillon, chief executive, said: “After considering all the evidence available, as well as the comments received during consultation on the earlier draft, the independent appraisal committee concluded that erlotinib is not an effective use of NHS resources when compared with either docetaxel or best supportive care. The committee was also concerned that erlotinib would not be as effective as the existing standard treatment, docetaxel.
“However, given the rapidly changing evidence base for erlotinib, the committee advised that the guidance should be considered for early review. Therefore this guidance will be reviewed in February 2008.
“The committee also recommends that further research be undertaken into subgroups for whom erlotinib may provide greater benefit.”
Subject to an appeal being received, final guidance to the NHS is expected in April.
Mike Unger, chief executive of the Roy Castle Lung Cancer Foundation, said: “We are obviously severely disappointed and disillusioned with NICE’s decision not to approve Tarceva purely on economic grounds. It’s the second blow that NICE has dealt to lung cancer patients in a month, following the announcement to decline Alimta — so there are now very few options left for lung cancer patients.”
Mr Unger added: “This leaves massive inconsistencies in treatment options for lung cancer patients in the UK. It’s absurd that Tarceva is available to certain patients in Scotland, but not the rest of the UK. Tarceva is used as a standard treatment in many other European countries and this should be the case here.”
Tarceva has been hailed by the medical profession as a big advance in a neglected area of cancer.
Approval battle
“ Tarceva can give some patients with lung cancer extra time, which can be extremely valuable to patients and their families”
Christine Akilade Senior nurse at Cancerbackup, the cancer support charity
“ The decision by NICE not to approve Tarceva is yet another negative decision for cancer patients, especially considering the fact that Scottish patients have had access to Tarceva since June 2006, after the Scottish Medicines Consortium recommended its use.
“ Other European countries have had access to this treatment for over a year whilst once again English and Welsh patients are losing precious time waiting for Tarceva to be made available to them.
“ It is critical that NICE and the Department of Health do not yet again cause cancer patients more misery and premature death by refusing proven treatment to patients”
Nick Thatcher Professor of Medical Oncology at the Christie Hospital Manchester
Win a luxury weekend to Newcastle and its neighbour Gateshead, find out more here
Risk, resilience and embracing new technology
Industry sectors news at a glance. Interactive heatmap, video and podcast
Discover the power of collective thinking. Submit a solution and be in with a chance to win a Media Hub Home Entertainment System
The inside track on current trends in the charity, not for profit and social enterprise sectors
Everything the Business Traveller needs to know to make a better trip
Make the most of the summer and enter our fabulous photographic competition, you could win a £5000 holiday
Corsica is an island of beauty and contrast, an ideal holiday destination
Enjoy further reading from Travel to Fashion, Business to Sport, discover more
Shortcuts to help you find sections and articles
The clever way to lease a new car is with Car leasing made simple™
2009
per month on 36-month
Personal Contract Hire (PCH)
2008
42850
Car Insurance
£24,250 - £30,346
MI5
London
£60,000
The Environment Agency
Bristol
Up to £90K
Boots
Midlands
OTE £85k
Credit Protection Association
Nationwide Opportunities
Completely London
Luxury Condo's in Manhattan with NYC views
The best new homes in Wimbledon?
Nationwide
Fabulous Cruise And Cruise & Stay Offers Including Virgin Atlantic Flights Prices Start From Only £699pp!
Last Minute Cruise And Cruise & Stay Offers. Med From £499pp, Caribbean From £699pp!
5 star quality at a 3 star price.
8 fabulous Canadian cities ...you won’t find cheaper
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths | Subscriptions | E-paper
News International associated websites: Globrix Property Search | Property Finder | Milkround
Copyright 2009 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.
My family are having to pay for my Father's Tarceva - he has stage 4 NSCLC and chemo didnt work for him. They gave him 2 months to live and said that Tarceva was his only hope - my Father is living on a pension so couldnt afford to pay for this treatment. If it wasnt for my Sister my Dad wouldnt be able to have this drug - I dont know what the outcome will be but I do know that now my Father has hope and quality of life.
Dawn, Newcastle, UK
I am shocked and disgusted from Anon's remark. Thanks to you Dr Paul Burt for putting Anon in there place. No wonder they did not want to put a name to that post, Clearly they are not in this position. I am currently fighting for this Drug for my husband we are having the fund it ourselves at the moment at an enormous cost. He has adenocarcinoma and since starting this drug only 7 days ago we have seen a remarkable difference. He is pain free!!! No pain killers at all! He is not breathless. This drug has already made a huge difference to him. We not have to worry about finding more money. I have set up a support website for others fighting for tarceva http://www.lc-action4life.co.uk I really feel for others in the same position not only do we have the worry of this awful disease we now have to worry about money. Lung Cancer patients charter stater that patients be given rapid access to up to date treatments! Yet we are having to fight for just that!
Deanne, South Shields, Tyne & Wear
how much would this drug cost to buy private as my auntie has lung cancer and if this drug is the only thing that will prolong her life the price is not a problem.
tracey, ipswich, suffolk
This drug together with another avastin has kept my husband alive despite being told by nhs oncologists that we should enjoy the summer implying it was his last (that was three years ago), and last year asked to take it "on the chin" that death was near. Not only is my husband alive but in good health. He has lung cancer and is a neversmoker. We have resources to pay for these drugs otherwise the nhs offers "best supportive care" ie death.
I sincerely hope nice members or those in the government who implement this do not get lung cancer. Or if they do are they going to die quietly.
J Ross, Harpenden, uk
my gran has lung cancer and she has a short while to live.
why does the govermant have to think about money before lives.if the goverment wants to think about money all the time then they should come face to face with the cancer victems.
wayne rowland, glossop, England
How dare polticians and their appointees play snakes and ladders with our health! There should be every effort made to increase the number of ladders, and every effort to eliminate the snakes. If value for money is their war cry, divert the massive funds still being wasted on the immoral and unwinnable Iraq war to our war on disease and illness at home - a truly noble and necessary cause.
Tim Newman, Callington, UK
In situations like this we should not blame NICE for not paying for the drug but we should blame the patent holder for charging so much for it. Tarceva is like anything else in a free enterprise economy, if it is fairly priced it will be bought, If the price is to high people will do with out it
Bob Yaes, Gaithersburg, USA/MD
Many drugs are approved for use in Scotland by NICE's equivalent body. If yehy are considered cost effective for the Scots, why are they not for the English? Is NICE itself cost effective? Why don't we abolish it, and ask the Sots to evaluate medicines fot the whole of the UK?
bob wilkinson, milnthorpe, Cumbria
The neo-liberal, neo-con agenda of the present capitalist era makes EVERYTHING an economic decision. How absurd of anyone to think that cancer patients wouldn't be subjected to the same trade-offs as any other segment of the political economy.
I'm fairly sure that a rich cancer sufferer will obtain all the Tarceva he or she could want. It's only money.
Tom Duncan, Astoria, OR/USA
If something is 'free' at the point of demand then there will be an imbalance between supply and demand and you must ration. This is a basic principle of economics taught to me when I was 14. Unfortunately this seems to be beyond most politicians.
The NHS will only be able to deliver drugs like this when people have to pay a significant portion of the cost and then they will make the decisions that NICE effectively does on their behalf and understand why they are being made, rather than just bleating they can't get something for free which has an significant cost.
Damian, London,
Why don't we scrap NICE and ask the Scots to advise on treatments and medication?
It would be quicker and cheaper (how cost effective is NICE?); and English and Welsh patients would not be disadvantaged, as they are at present.
bob wilkinson, milnthorpe, Cumbria
The comment from Anon is way off the mark. We know which patients are likely to benefit from Tarceva (either life long non smokers, females, adenocarcinoma pathology type and South East Asian origin)and the minimum NICE should have allowed is for them to have access to it. Responses are usually very quick so stopping the drug early in nonresponders cuts down expense. I have patients whose existance depends on Tarceva. Thank God I started them on this drug before this ridiculous decision. What is the point in doing any more cancer research when virtually every new treatment is denied to the patients by what is actually the Nasty Institute of Cost Effectiveness.
Dr Paul Burt, Manchester, UK
I agree that Tarceva, and other molecularly targeted drugs, offer 'a big advance in a neglected area of cancer,' and that it is extremely valuable to the subset of patients in which it works.
This subset of patients, however, is small, and possible to pre-select. The overall effect of treating the general lung cancer population is not enough to justify the array of other more effective treatments (in cancer or other disease patients) that could be prescribed for the same cost.
Considering the design of such drugs to target a specific molecular mechanism, approval should go hand in hand with research (for which the technology is available in pharma) towards testing for these mechanisms, and thus to identify the subset of patients who have a chance of benefiting.
I applaud this brave decision by NICE, and hope, along with the approval of Herceptin with it's associated diagnostic for responders, this decision sends the right message to health care professionals.
Anon, Manchester,
My father died last june; he had lung cancer which was diagnosed too late and had spread everywhere. The specialists couldn't understand how he had managed to feel reasonably well for so long before deciding to have a check-up. He died six weeks after the first visit. However, more attention to palliative treatment is required, since his deterioration was drastic and painful, and we were told there was absolutely nothing that could have been done to make it any easier. There's got to be something.
Martin Gaudiano, Caserta, Italy
A minimum cost of of £25 Billion projected to be the cost of the early stages of developing another Trident missile and we cant afford to treat lung cancer sufferers ? Government policies (withdrawing finance for caring for the elderly at home , etc) will reduce the quality of life for many people.
It is appalling that a Government can make a decision to refuse treatment to cancer patients.
Curious that it's lung cancer, of course it would be very cynical of me to suspect a link to smoking having anything to do with that decision, wouldn't it ? !!
A Wood, Mid Wales,
What did Blair say 'Heath,Heath ,Heath'
he didn't say whose.
He meant War, War, War.
It is incredible what a mess Blair has made of this once fine country in ten long years
Ian, Leicester, England
My God,we have billions for the War in Iraq,but we have nothing for cancer sufferers who have paid thousands in Tax over their working lives.
A disgrace.
Michael Rigby, Blackburn, England
Would an MP or any other government official be refused this treatment ? I doubt it. Yet another example of nasty NICE.
Steve P, Leeds, England